Results 191 to 200 of about 14,066,519 (402)

CLINICAL DEVELOPMENT STRATEGY FOR COPIES OF PREVIOUSLY REGISTERED DRUGS. PART 3. PROTOCOL OF CLINICAL TRIAL OF BIOEQUIVALENCE

Разработка и регистрация лекарственных средств, 2019
Recommendations presented in the article are based on current regulations and guidelines of regulatory authorities on clinical trials of bioequivalence and professional experience of authors and will be useful for medical writers to plan clinical trial ...
K. A. Yatsenko, E. A. Kuznetsov, A. V. Arkadjeva, V. S. Berezina   +3 more
doaj  

Reporting clinical trials [PDF]

Rheumatology, 1983
J S, Dixon, A, Smith, S J, Evans
openaire   +2 more sources

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

Explore thyself: is it time for metacognition screening in clinical trials? [PDF]

Clin Park Relat Disord
McGarry A, Kim SYH, Auinger P, Venuto C, Gaughan J.   +4 more
europepmc   +1 more source

(ID: 262) Utilising research management technology to streamline and integrate pharmacy clinical trial processes within a multi-disciplinary research team: a service evaluation [PDF]

Youssef Essra, Yeomans Angela, Rikunenko Rachel   +2 more
openalex   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Antiviral treatment in adult patients hospitalized for influenza: study protocol for a multi-center, randomized, placebo-controlled trial on the efficacy of baloxavir marboxil to reduce time to clinical improvement and the risk for severe complications (the INFLUENT trial) [PDF]

Krisztina Hosszu-Fellous, Antoine Poncet, Ana Rita Goncalves Cabecinhas, Manuel Schibler, Benjamin Meyer, Virginie Prendki, Angela Huttner, Sebastian Carballo, Mathias Pouillon, Ksenija Slankamenac, Pierre-Alexandre Bart, Enos Bernasconi, Oriol Manuel, Matteo Mombelli, Nicolas J. Mueller, Laurent Kaiser, Pauline Vetter   +16 more
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Commentary: Multi-stage consent for time-sensitive clinical trials. [PDF]

Clin Trials
Karel D, Wendler D.
europepmc   +1 more source